Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 12/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13102993 | 0.92 | TPSAB1 (0.40) | DRD2DRD3NAMPTACACBACACA | |
| SCHEMBL14820354 | 0.84 | EGLN1 (0.44) | DRD2DRD3CHRM3NAMPTSSTR4 | |
| SCHEMBL14252407 | 0.84 | ACACB (0.43) | ACACBACACA | |
| SCHEMBL14421972 | 0.84 | TPSAB1 (0.39) | ACACBACACA | |
| SCHEMBL14805889 | 0.82 | ACACB (0.39) | DRD2DRD3ACACBACACA | |
| SCHEMBL31420630 | 0.81 | CYP2D6 (0.44) | DRD2DRD3CHRM3NAMPTSSTR4 | |
| SCHEMBL856649 | 0.81 | CYP2D6 (0.44) | DRD2DRD3CHRM3NAMPTSSTR4 | |
| SCHEMBL13387503 | 0.81 | TDP1 (0.48) | ACACBACACA | |
| SCHEMBL8392106 | 0.81 | TDP1 (0.48) | ACACBACACA | |
| SCHEMBL16020328 | 0.79 | DRD2 (0.47) | DRD2NAMPTACACBACACASSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9481675-B2 | Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | DRD2 4210/4885DRD3 3169/4885CHRM3 1602/4885 |
| US-20130079323-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | DRD2 4210/4885DRD3 3169/4885CHRM3 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.